US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist

0.930
-0.018-1.90%

Close Jun 20 16:00 ET

13.22MMarket Cap-603P/E (TTM)

Chemomab Therapeutics Stock Forum

Trytosaveabit

Jun 18 06:01

$Chemomab Therapeutics(CMMB.US)$ Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis

Trytosaveabit

Jun 6 12:52

Low volume fall, even with good data released at conference!

$Chemomab Therapeutics(CMMB.US)$ Im still bullish and look forward to the PHASE 2 Topline data readout! NFA Just thinking outloud
TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clin...

Trytosaveabit

May 9 06:06

Note the timeline

$Chemomab Therapeutics(CMMB.US)$ Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update ─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publications Based on Patient Sample Studies Further Reinforce the Key Role of Chemomab’s Novel ...

Trytosaveabit

May 8 06:22

Update

$Chemomab Therapeutics(CMMB.US)$ Chemomab Therapeutics Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule

Trytosaveabit

Apr 18 06:13

Watching for the data

$Chemomab Therapeutics(CMMB.US)$ Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis

Stock Region

Mar 25 17:48

Therapeutics Company Awarded Patent For Breakthrough Liver Disease Treatment

Breakthrough in Liver Disease Treatment: Chemomab's CM-101 Secures New European Patent.
In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...

Trytosaveabit

Mar 7 14:42

Pretty nice!

$Chemomab Therapeutics(CMMB.US)$ Waiting for the rest of the numbers! (((((. Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losses of $(0.72) per share from the same period last year. )))))

Trytosaveabit

Feb 20 06:28

Finally the news! Hehehe

$Chemomab Therapeutics(CMMB.US)$

Trytosaveabit

Feb 20 06:11

Boom

$Chemomab Therapeutics(CMMB.US)$

Trytosaveabit

Jan 3 06:03

Update

$Chemomab Therapeutics(CMMB.US)$Chemomab Announces Completion Of Patient Enrollment In CM-101 Phase 2 Primary Sclerosing Cholangitis Trial And Moves Up Expected Topline Readout To Midyear 2024

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

Concept

Top Gainers Yesterday

Intraday-0.59%